+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

Hydroxychloroquine - Global Market Outlook (2018-2027)

  • ID: 5050745
  • Report
  • May 2020
  • Region: Global
  • 140 pages
  • Stratistics Market Research Consulting Pvt Ltd
10% Free customization

This report comes with 10% free customization, enabling you to add data that meets your specific business needs.

1 of 4

Enquire about COVID-19 updates for this product.

Enquire Now

FEATURED COMPANIES

  • Cadila Healthcare Ltd
  • Hikma Pharmaceuticals PLC
  • Ipca Laboratories Ltd
  • Mylan N.V
  • Novartis AG
  • Sanofi S.A
  • MORE
The Global Hydroxychloroquine market accounted for $41.30 million in 2018 and is expected to reach $100.62 million by 2027 growing at a CAGR of 10.4% during the forecast period. The rising geriatric population, and the high demand for the drug from third world nations for dealing with malarial are the major factors propelling the market growth. However, factors such as product recalls and discontinuation of drugs are hampering the market growth.

Hydroxychloroquine is a medication and analogue of chloroquine. It has antirheumatic as well as antimalarial properties. It has been used widely for the treatment of infectious as well as rheumatoid arthritis. It has been recognized that clinical use of hydroxychloroquine has significantly improve the treatment rate of patient suffering from the COVID-19. The growth of hydroxychloroquine enhanced by the growing cases of infectious diseases that majorly includes coronavirus and malaria and increase research and development activities. In addition, advances in the treatment options and the presence of well-established healthcare facilities are some of the impacting factors for the demand of hydroxychloroquine drugs.

Based on the application, the COVID-19 segment is going to have a lucrative growth during the forecast period as this is a new condition and a large number of trials are conducted on the effectiveness of the medicine in treating the condition, it would contribute to the growth rate witnessed by this segment. The fact that a large number of patients with COVID-19 are admitted to hospitals for treatment results in high preference and dependence on this medicine, contributing to the market share held by this segment.

By geography, Asia Pacific is going to have a lucrative growth during the forecast period attributed to India being the leading producer of the drug and China being the largest exporter of the raw materials for the drug production. Apart from this, it is cost-effective drug in India costing nearly lesser than rupees three per tablet. Moreover, the drug has been advocated in countries like India as a measure to prevent the coronavirus in people who have been in contact with COVID positive persons and those falling in high risk zone. All these aforementioned aspects are likely to favorably leverage the growth of the Hydroxychloroquine market over the forecast period.

Some of the key players profiled in the Hydroxychloroquine Market include Hikma Pharmaceuticals PLC, Cadila Healthcare Ltd, Ipca Laboratories Ltd, Novartis AG, Mylan N.V, Sanofi S.A, Taj Pharmaceuticals Ltd, Shanghai Pharmaceuticals Holding Co., Ltd, Torrent Pharmaceuticals Ltd, Teva Pharmaceutical Industries Ltd, Dr. Reddy’s Laboratories Ltd, Sun Pharmaceutical Industries Ltd, and Zydus Cadila.

Types Covered:
  • Tablets
  • Injection
Route of Administrations Covered:
  • Oral
  • Intravenous
Grades Covered:
  • United States Pharmacopeial Convention (USP) Standards Grade
  • Pharmaceutical Standards Grade
European Pharmacopoeia (EP) Standards Grade

Strengths Covered:
  • 100 mg
  • 200 mg
  • 250 mg
  • 400 mg
  • 500 mg
  • 800 mg
Distribution Channels Covered:
  • Hospital Pharmacy
  • Online Pharmacy
  • Speciality Drug Stores
  • Retail Pharmacy
  • Homeocare
Applications Covered:
  • Malaria
  • Rheumatoid arthritis
  • Lupus Erythematosus
  • Skin Lesions
  • COVID-19
Regions Covered:

North America
  • US
  • Canada
  • Mexico
Europe
  • Germany
  • UK
  • Italy
  • France
  • Spain
  • Rest of Europe
Asia Pacific
  • Japan
  • China
  • India
  • Australia
  • New Zealand
  • South Korea
  • Rest of Asia Pacific
South America
  • Argentina
  • Brazil
  • Chile
  • Rest of South America
Middle East & Africa
  • Saudi Arabia
  • UAE
  • Qatar
  • South Africa
  • Rest of Middle East & Africa
What our report offers:
  • Market share assessments for the regional and country-level segments
  • Strategic recommendations for the new entrants
  • Covers Market data for the years 2017, 2018, 2019, 2023 and 2027
  • Market Trends (Drivers, Constraints, Opportunities, Threats, Challenges, Investment Opportunities, and recommendations)
  • Strategic recommendations in key business segments based on the market estimations
  • Competitive landscaping mapping the key common trends
  • Company profiling with detailed strategies, financials, and recent developments
  • Supply chain trends mapping the latest technological advancements
Free Customization Offerings:

Purchasers of this report will be entitled to receive one of the following free customization options:

1. Company Profiling
  • Comprehensive profiling of additional market players (up to 3)
  • SWOT Analysis of key players (up to 3)
2. Regional Segmentation
  • Market estimations, Forecasts and CAGR of any prominent country as per the client's interest (Note: Depends on feasibility check)
3. Competitive Benchmarking
  • Benchmarking of key players based on product portfolio, geographical presence, and strategic alliances

This report will be delivered within 2 business days.
Note: Product cover images may vary from those shown
2 of 4

FEATURED COMPANIES

  • Cadila Healthcare Ltd
  • Hikma Pharmaceuticals PLC
  • Ipca Laboratories Ltd
  • Mylan N.V
  • Novartis AG
  • Sanofi S.A
  • MORE
1 Executive Summary

2 Preface
2.1 Abstract
2.2 Stake Holders
2.3 Research Scope
2.4 Research Methodology
2.4.1 Data Mining
2.4.2 Data Analysis
2.4.3 Data Validation
2.4.4 Research Approach
2.5 Research Sources
2.5.1 Primary Research Sources
2.5.2 Secondary Research Sources
2.5.3 Assumptions

3 Market Trend Analysis
3.1 Introduction
3.2 Drivers
3.3 Restraints
3.4 Opportunities
3.5 Threats
3.6 Application Analysis
3.7 Emerging Markets
3.8 Impact of Covid-19

4 Porters Five Force Analysis
4.1 Bargaining power of suppliers
4.2 Bargaining power of buyers
4.3 Threat of substitutes
4.4 Threat of new entrants
4.5 Competitive rivalry

5 Global Hydroxychloroquine Market, By Type
5.1 Introduction
5.2 Tablets
5.3 Injection

6 Global Hydroxychloroquine Market, By Route of Administration
6.1 Introduction
6.2 Oral
6.3 Intravenous

7 Global Hydroxychloroquine Market, By Grade
7.1 Introduction
7.2 United States Pharmacopeial Convention (USP) Standards Grade
7.3 Pharmaceutical Standards Grade
7.4 European Pharmacopoeia (EP) Standards Grade

8 Global Hydroxychloroquine Market, By Strength
8.1 Introduction
8.2 100 mg
8.3 200 mg
8.4 250 mg
8.5 400 mg
8.6 500 mg
8.7 800 mg

9 Global Hydroxychloroquine Market, By Distribution Channel
9.1 Introduction
9.2 Hospital Pharmacy
9.3 Online Pharmacy
9.4 Speciality Drug Stores
9.5 Retail Pharmacy
9.6 Homeocare

10 Global Hydroxychloroquine Market, By Application
10.1 Introduction
10.2 Malaria
10.3 Rheumatoid arthritis
10.4 Lupus Erythematosus
10.4.1 Systemic Lupus Erythematosus
10.4.2 Chronic Discoid Lupus Erythematosus
10.5 Skin Lesions
10.6 COVID-19

11 Global Hydroxychloroquine Market, By Geography
11.1 Introduction
11.2 North America
11.2.1 US
11.2.2 Canada
11.2.3 Mexico
11.3 Europe
11.3.1 Germany
11.3.2 UK
11.3.3 Italy
11.3.4 France
11.3.5 Spain
11.3.6 Rest of Europe
11.4 Asia Pacific
11.4.1 Japan
11.4.2 China
11.4.3 India
11.4.4 Australia
11.4.5 New Zealand
11.4.6 South Korea
11.4.7 Rest of Asia Pacific
11.5 South America
11.5.1 Argentina
11.5.2 Brazil
11.5.3 Chile
11.5.4 Rest of South America
11.6 Middle East & Africa
11.6.1 Saudi Arabia
11.6.2 UAE
11.6.3 Qatar
11.6.4 South Africa
11.6.5 Rest of Middle East & Africa

12 Key Developments
12.1 Agreements, Partnerships, Collaborations and Joint Ventures
12.2 Acquisitions & Mergers
12.3 New Product Launch
12.4 Expansions
12.5 Other Key Strategies

13 Company Profiling
13.1 Hikma Pharmaceuticals PLC
13.2 Cadila Healthcare Ltd
13.3 Ipca Laboratories Ltd
13.4 Novartis AG
13.5 Mylan N.V
13.6 Sanofi S.A
13.7 Taj Pharmaceuticals Ltd
13.8 Shanghai Pharmaceuticals Holding Co., Ltd
13.9 Torrent Pharmaceuticals Ltd
13.10 Teva Pharmaceutical Industries Ltd
13.11 Dr. Reddy’s Laboratories Ltd
13.12 Sun Pharmaceutical Industries Ltd
13.13 Zydus Cadila

List of Tables
Table 1 Global Hydroxychloroquine Market Outlook, By Region (2017-2027) ($MN)
Table 2 Global Hydroxychloroquine Market Outlook, By Type (2017-2027) ($MN)
Table 3 Global Hydroxychloroquine Market Outlook, By Tablets (2017-2027) ($MN)
Table 4 Global Hydroxychloroquine Market Outlook, By Injection (2017-2027) ($MN)
Table 5 Global Hydroxychloroquine Market Outlook, By Route of Administration (2017-2027) ($MN)
Table 6 Global Hydroxychloroquine Market Outlook, By Oral (2017-2027) ($MN)
Table 7 Global Hydroxychloroquine Market Outlook, By Intravenous (2017-2027) ($MN)
Table 8 Global Hydroxychloroquine Market Outlook, By Grade (2017-2027) ($MN)
Table 9 Global Hydroxychloroquine Market Outlook, By United States Pharmacopeial Convention (USP) Standards Grade (2017-2027) ($MN)
Table 10 Global Hydroxychloroquine Market Outlook, By Pharmaceutical Standards Grade (2017-2027) ($MN)
Table 11 Global Hydroxychloroquine Market Outlook, By European Pharmacopoeia (EP) Standards Grade (2017-2027) ($MN)
Table 12 Global Hydroxychloroquine Market Outlook, By Strength (2017-2027) ($MN)
Table 13 Global Hydroxychloroquine Market Outlook, By 100 mg (2017-2027) ($MN)
Table 14 Global Hydroxychloroquine Market Outlook, By 200 mg (2017-2027) ($MN)
Table 15 Global Hydroxychloroquine Market Outlook, By 250 mg (2017-2027) ($MN)
Table 16 Global Hydroxychloroquine Market Outlook, By 400 mg (2017-2027) ($MN)
Table 17 Global Hydroxychloroquine Market Outlook, By 500 mg (2017-2027) ($MN)
Table 18 Global Hydroxychloroquine Market Outlook, By 800 mg (2017-2027) ($MN)
Table 19 Global Hydroxychloroquine Market Outlook, By Distribution Channel (2017-2027) ($MN)
Table 20 Global Hydroxychloroquine Market Outlook, By Hospital Pharmacy (2017-2027) ($MN)
Table 21 Global Hydroxychloroquine Market Outlook, By Online Pharmacy (2017-2027) ($MN)
Table 22 Global Hydroxychloroquine Market Outlook, By Speciality Drug Stores (2017-2027) ($MN)
Table 23 Global Hydroxychloroquine Market Outlook, By Retail Pharmacy (2017-2027) ($MN)
Table 24 Global Hydroxychloroquine Market Outlook, By Homeocare (2017-2027) ($MN)
Table 25 Global Hydroxychloroquine Market Outlook, By Application (2017-2027) ($MN)
Table 26 Global Hydroxychloroquine Market Outlook, By Malaria (2017-2027) ($MN)
Table 27 Global Hydroxychloroquine Market Outlook, By Rheumatoid arthritis (2017-2027) ($MN)
Table 28 Global Hydroxychloroquine Market Outlook, By Lupus Erythematosus (2017-2027) ($MN)
Table 29 Global Hydroxychloroquine Market Outlook, By Systemic Lupus Erythematosus (2017-2027) ($MN)
Table 30 Global Hydroxychloroquine Market Outlook, By Chronic Discoid Lupus Erythematosus (2017-2027) ($MN)
Table 31 Global Hydroxychloroquine Market Outlook, By Skin Lesions (2017-2027) ($MN)
Table 32 Global Hydroxychloroquine Market Outlook, By COVID-19 (2017-2027) ($MN)

Note: Tables for North America, Europe, APAC, South America, and Middle East & Africa Regions are also represented in the same manner as above.
Note: Product cover images may vary from those shown
3 of 4
  • Hikma Pharmaceuticals PLC
  • Cadila Healthcare Ltd
  • Ipca Laboratories Ltd
  • Novartis AG
  • Mylan N.V
  • Sanofi S.A
  • Taj Pharmaceuticals Ltd
  • Shanghai Pharmaceuticals Holding Co., Ltd
  • Torrent Pharmaceuticals Ltd
  • Teva Pharmaceutical Industries Ltd
  • Dr. Reddy’s Laboratories Ltd
  • Sun Pharmaceutical Industries Ltd
  • Zydus Cadila
Note: Product cover images may vary from those shown
4 of 4

Loading
LOADING...

Adroll
adroll